宫颈癌预防的新进展：疗效、效果、消除？
Advances in cervical cancer prevention: Efficacy, effectiveness, elimination?
机构信息
Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm, Sweden.
Regional Cancer Center Stockholm-Gotland, Stockholm, Sweden.
出版信息
PLoS Med. 2020 Jan 28;17(1):e1003035. doi: 10.1371/journal.pmed.1003035. eCollection 2020 Jan.
Abstract
With major advances in understanding the infectious etiology of cervical cancer, preventive medicine has obtained highly promising new tools. Human papillomavirus (HPV) vaccines, together with a growing arsenal of HPV-based screening tests, have the potential to radically change public health but require diligent, large-scale implementation to reach the final goal: the elimination of cervical cancer. We reflect here upon the state of cervical cancer prevention globally as there have been several recent developments that will inform this implementation process.
摘要
随着对宫颈癌感染病因认识的重大进展，预防医学获得了极具前景的新工具。人乳头瘤病毒（HPV）疫苗，以及日益增多的 HPV 筛查检测手段，有可能从根本上改变公共卫生状况，但需要大力、大规模地实施，以实现最终目标：消除宫颈癌。最近有一些新的进展，将为这一实施过程提供信息，我们在此对全球宫颈癌预防状况进行反思。
相似文献
1
Advances in cervical cancer prevention: Efficacy, effectiveness, elimination?宫颈癌预防的新进展：疗效、效果、消除？
PLoS Med. 2020 Jan 28;17(1):e1003035. doi: 10.1371/journal.pmed.1003035. eCollection 2020 Jan.
2
Towards cervical cancer eradication: joint force of HPV vaccination and HPV-based cervical cancer screening.迈向消除宫颈癌：HPV疫苗接种与基于HPV的宫颈癌筛查的联合力量
Clin Microbiol Infect. 2015 Sep;21(9):806-7. doi: 10.1016/j.cmi.2015.05.041. Epub 2015 Jun 9.
3
The rationale for implementation of HPV testing in routine cervical screening in Romania.罗马尼亚在常规宫颈癌筛查中实施人乳头瘤病毒（HPV）检测的基本原理。
Rev Med Chir Soc Med Nat Iasi. 2013 Apr-Jun;117(2):293-6.
4
Screening for cervical cancer and human papillomavirus vaccination in Israel: recommendations.以色列宫颈癌筛查与人乳头瘤病毒疫苗接种：建议
Vaccine. 2013 Nov 22;31 Suppl 8:I58-60. doi: 10.1016/j.vaccine.2013.07.048.
5
Human papillomavirus vaccines: new tools for accelerating cervical cancer prevention in developing countries.人乳头瘤病毒疫苗：发展中国家加速宫颈癌预防的新工具。
Immunotherapy. 2009 Sep;1(5):795-807. doi: 10.2217/imt.09.48.
6
[Expert consensus on immunoprophylaxis of human papillomavirus-related diseases (abridged)].人乳头瘤病毒相关疾病免疫预防专家共识（节略版）
Zhonghua Yu Fang Yi Xue Za Zhi. 2019 Dec 6;53(12):1218-1235. doi: 10.3760/cma.j.issn.0253-9624.2019.12.006.
7
The combined impact of implementing HPV immunisation and primary HPV screening in New Zealand: Transitional and long-term benefits, costs and resource utilisation implications.新西兰实施 HPV 免疫接种和初级 HPV 筛查的综合影响：过渡和长期效益、成本和资源利用的影响。
Gynecol Oncol. 2019 Mar;152(3):472-479. doi: 10.1016/j.ygyno.2018.10.045.
8
Infrastructure requirements for human papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa.撒哈拉以南非洲地区人乳头瘤病毒疫苗接种和宫颈癌筛查的基础设施要求。
Vaccine. 2013 Dec 29;31 Suppl 5:F47-52. doi: 10.1016/j.vaccine.2012.06.066.
9
Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges.预防性人乳头瘤病毒疫苗接种与宫颈癌的一级预防：问题与挑战。
Clin Microbiol Infect. 2012 Oct;18 Suppl 5:64-9. doi: 10.1111/j.1469-0691.2012.03946.x. Epub 2012 Aug 6.
10
European consensus statement on "HPV Vaccination and Colposcopy".欧洲人关于 HPV 疫苗接种和阴道镜检查的共识声明。
J Low Genit Tract Dis. 2011 Oct;15(4):309-15. doi: 10.1097/LGT.0b013e318222b2c4.
引用本文的文献
1
HPV16/HPV58 viral load is non-linearly correlated with cervical lesions and can be used as a triage marker.人乳头瘤病毒16型/人乳头瘤病毒58型病毒载量与宫颈病变呈非线性相关，可作为一种分流标志物。
Infect Agent Cancer. 2025 Jul 22;20(1):48. doi: 10.1186/s13027-025-00684-w.
2
Trends in cervical cancer incidence and mortality in the United States, 1975-2018: a population-based study.1975 - 2018年美国宫颈癌发病率和死亡率趋势：一项基于人群的研究
Front Med (Lausanne). 2025 Apr 30;12:1579446. doi: 10.3389/fmed.2025.1579446. eCollection 2025.
3
Misconceptions and knowledge gaps about HPV, cervical cancer, and HPV vaccination among central American immigrant parents in the United States.美国中美洲移民父母对人乳头瘤病毒（HPV）、宫颈癌及HPV疫苗接种的误解与知识空白
Hum Vaccin Immunother. 2025 Dec;21(1):2494452. doi: 10.1080/21645515.2025.2494452. Epub 2025 Apr 28.
4
Advances in the Prevention of Cervical Cancer by Anti-Human Papillomavirus Agents.抗人乳头瘤病毒制剂预防宫颈癌的进展
Cancer Med. 2025 Apr;14(7):e70847. doi: 10.1002/cam4.70847.
5
Exploring the therapeutic potency of cryptotanshinone in cervical cancer: a multi-omics and network pharmacology approach.探索隐丹参酮对宫颈癌的治疗潜力：一种多组学和网络药理学方法。
Front Genet. 2024 Nov 27;15:1435132. doi: 10.3389/fgene.2024.1435132. eCollection 2024.
6
TBP activates DCBLD1 transcription to promote cell cycle progression in cervical cancer.TBP 激活 DCBLD1 转录，促进宫颈癌中的细胞周期进程。
Funct Integr Genomics. 2024 Nov 26;24(6):221. doi: 10.1007/s10142-024-01496-8.
7
Global burden of gynaecological cancers in 2022 and projections to 2050.2022 年全球妇科癌症负担及 2050 年预测。
J Glob Health. 2024 Aug 16;14:04155. doi: 10.7189/jogh.14.04155.
8
Cervical Cancer and Its Association With Pregnancy.宫颈癌及其与妊娠的关联。
Cureus. 2024 Jun 11;16(6):e62144. doi: 10.7759/cureus.62144. eCollection 2024 Jun.
9
The effect of refined psychological pain nursing combined with IMB nursing on the pain, sleep and quality of life of patients after cervical cancer surgery.精细心理疼痛护理联合 IMB 护理对宫颈癌术后患者疼痛、睡眠及生活质量的影响。
Medicine (Baltimore). 2024 Apr 19;103(16):e37816. doi: 10.1097/MD.0000000000037816.
10
Oct4 activates IL-17A to orchestrate M2 macrophage polarization and cervical cancer metastasis.Oct4 激活 IL-17A 以协调 M2 巨噬细胞极化和宫颈癌转移。
Cancer Immunol Immunother. 2024 Mar 2;73(4):73. doi: 10.1007/s00262-023-03596-z.
本文引用的文献
1
Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices.人乳头瘤病毒疫苗接种：免疫实践咨询委员会的最新建议。
MMWR Morb Mortal Wkly Rep. 2019 Aug 16;68(32):698-702. doi: 10.15585/mmwr.mm6832a3.
2
Communication around HPV vaccination for adolescents in low- and middle-income countries: a systematic scoping overview of systematic reviews.中低收入国家青少年 HPV 疫苗接种相关沟通：系统评价的系统综述概述。
Syst Rev. 2019 Aug 1;8(1):190. doi: 10.1186/s13643-019-1100-y.
3
Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis.人群水平影响和 herd 效应：人乳头瘤病毒疫苗接种计划引入后的更新系统评价和荟萃分析。
Lancet. 2019 Aug 10;394(10197):497-509. doi: 10.1016/S0140-6736(19)30298-3. Epub 2019 Jun 26.
4
Eradication of human papillomavirus and elimination of HPV-related diseases - scientific basis for global public health policies.消除人乳头瘤病毒和消除与 HPV 相关的疾病 - 全球公共卫生政策的科学依据。
Expert Rev Vaccines. 2019 Feb;18(2):153-160. doi: 10.1080/14760584.2019.1568876. Epub 2019 Feb 7.
5
Is the positive predictive value of high-grade cytology in predicting high-grade cervical disease falling due to HPV vaccination?高级别细胞学检查预测高级别宫颈疾病的阳性预测值是否因 HPV 疫苗接种而降低？
Int J Cancer. 2019 Jun 15;144(12):2964-2971. doi: 10.1002/ijc.32050. Epub 2019 Jan 11.
6
Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses.利用 HPV 自我采样检测来发现宫颈癌前病变并覆盖未筛查人群：更新的荟萃分析。
BMJ. 2018 Dec 5;363:k4823. doi: 10.1136/bmj.k4823.
7
The projected timeframe until cervical cancer elimination in Australia: a modelling study.澳大利亚消除宫颈癌的预计时间框架：建模研究。
Lancet Public Health. 2019 Jan;4(1):e19-e27. doi: 10.1016/S2468-2667(18)30183-X. Epub 2018 Oct 2.
8
The New HPV Vaccination Policy in France.法国的新HPV疫苗接种政策。
N Engl J Med. 2018 Mar 22;378(12):1160. doi: 10.1056/NEJMc1801036.
9
Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis.全球各地区和收入水平的人乳头瘤病毒疫苗接种覆盖率估计：汇总分析。
Lancet Glob Health. 2016 Jul;4(7):e453-63. doi: 10.1016/S2214-109X(16)30099-7.
10
HPV immunisation and cervical screening--confirmation of changed performance of cytology as a screening test in immunised women: a retrospective population-based cohort study.人乳头瘤病毒免疫接种与宫颈癌筛查——免疫接种女性中作为筛查检测的细胞学检查性能变化的确认：一项基于人群的回顾性队列研究
Br J Cancer. 2016 Mar 1;114(5):582-9. doi: 10.1038/bjc.2015.474. Epub 2016 Feb 4.
Zotero 插件